RSV Vaccine Guidance for Older Adults | RSV | CDC - Centers for …
WEBAug 30, 2024 · What to know. CDC recommends a single dose of any FDA-licensed RSV vaccine for all adults ages 75 and older and adults ages 60–74 at increased risk of severe RSV. Three RSV vaccines are currently available for adults ages 60 and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo.
The new RSV vaccines for older adults - Mayo Clinic Press
WEBSep 19, 2023 · Arexvy: GSK’s RSV vaccine. Let’s start with GSK’s Arexvy. A study of 24,966 participants showed that Arexvy had an overall efficacy of 82.6% in preventing lower respiratory tract disease — such as pneumonia — caused by RSV.
Arexvy RSV Vaccine: The 200 Best Inventions of 2023 - TIME
WEBOct 24, 2023 · Find out why Arexvy RSV Vaccine is one of the best inventions of 2023.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · For Immediate Release: May 03, 2023. Español. Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United...
New Data for Arexvy Shows Vaccine Efficacy Through 3 RSV …
WEB22 hours ago · A single dose of the GSK vaccine Arexvy against respiratory syncytial virus (RSV) showed positive safety and efficacy data for protection over 3 RSV seasons for adults aged 60 years and older, including those at increased risk of severe disease, according to a company announcement.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older …
WEBFeb 15, 2023 · Respiratory syncytial virus (RSV) is an important cause of acute respiratory infections during the autumn and winter months in temperate regions and during rainy seasons in tropical regions. 1,2...
Arexvy for Respiratory Syncytial Virus Prevention - WebMD
WEB7 min read. Arexvy was the first vaccine approved to prevent respiratory syncytial virus (RSV). RSV is a common virus that usually causes mild cold-like symptoms. These symptoms can be more...
GSK's Arexvy Vaccine Demonstrates Strong Efficacy Against RSV …
WEB22 hours ago · GSK has announced promising results for Arexvy, its respiratory syncytial virus (RSV) vaccine, showing a cumulative efficacy of 62.9% against RSV-related lower respiratory tract disease (RSV-LRTD) over three full …
About AREXVY | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBEFFECTIVE. in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease (COPD), chronic heart failure, advanced liver or kidney disease, or any chronic respiratory or pulmonary disease. For Those 60 Years and Older.
ACIP Evidence to Recommendations for Use of Protein Subunit …
WEBSep 5, 2024 · On May 3, 2023, the Food and Drug Administration (FDA) approved GSK's Arexvy for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged ≥60 years. 1 Arexvy is a 1-dose (0.5 mL) subunit vaccine containing stabilized RSV prefusion F protein in combination with adjuvant (AS01 E). 1.